Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Desmoid Tumors Market Revenue Outlook: What CAGR Is Expected Through 2030?
The market for desmoid tumors has experienced robust expansion lately, with projections indicating continued growth from $3.15 billion in 2025 to $3.35 billion in 2026, reflecting a compound annual growth rate of 6.1%. Factors contributing to this past growth include a limited understanding of these rare tumors, a primary dependence on surgical interventions, a shortage of medications specifically developed for these conditions, the predominant delivery of cancer care within hospital settings, and instances of delayed diagnoses.
The global market for desmoid tumors is projected for significant expansion over the coming years, anticipating a rise to $4.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.2%. This projected growth trajectory is underpinned by several key factors, including the continuous development of molecular therapies, the expanding pipeline of treatments for rare diseases, an increase in the number of clinical trials being conducted, enhancements in diagnostic imaging technologies, and the proliferation of specialized treatment centers. Emerging trends expected to shape this market during the forecast period encompass a notable shift toward non-surgical treatment approaches, increased adoption of targeted molecular therapies, a greater reliance on watchful waiting strategies, the broadening implementation of multidisciplinary care models, and an intensified emphasis on research into rare diseases.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp
Desmoid Tumors Market Growth Momentum: Which Factors Are Influencing Demand?
Global increases in cancer incidence are anticipated to be a primary driver for the desmoid tumor market’s expansion. Cancer, characterized by the uncontrolled proliferation and dissemination of abnormal bodily cells that can invade and damage adjacent tissues and organs, is a multifaceted group of diseases. The escalating global cancer burden has consequently bolstered the demand for sophisticated and efficacious chemotherapeutic treatments, thereby exerting a favorable impact on the desmoid tumor market. As an illustration, the UK’s National Health Service (NHS) reported in October 2025 that the United Kingdom recorded 354,820 new cancer diagnoses in 2023, averaging 972 daily cases, representing an increase of 8,605 over the preceding year. Consequently, the escalating prevalence of cancer serves as a significant impetus for the desmoid tumor market’s advancement.
Desmoid Tumors Market Segments: Where Are The Largest Growth Opportunities?
The desmoid tumors market covered in this report is segmented –
1) By Treatment: Surgery, Radiation Therapy, Anti-Inflammatory Medication, Hormone Therapy, Chemotherapy, Novel Molecular-Targeted Therapy, Other Treatments
2) By Diagnosis: Biopsy, Electron Microscopic Examination, Immunohistochemical Analysis, Other Diagnosis
3) By End-User: Hospitals And Clinics, Specialty Centers, Other End-Users
Subsegments:
1) By Surgery: Wide Excision, Minimally Invasive Surgery
2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy
3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Corticosteroids
4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors
5) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy
6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors
7) By Other Treatments: Watchful Waiting, Physical Therapy, Pain Management Strategies
Desmoid Tumors Market Trends Reshaping Industry Growth
Within the desmoid tumors market, key corporations are focused on creating cutting-edge pharmaceuticals, exemplified by nirogacestat, to address the requirements of their current customer base more effectively. This particular therapeutic agent, nirogacestat, functions as an orally administered, small-molecule inhibitor targeting gamma-secretase. To illustrate, SpringWorks Therapeutics Inc., a biopharmaceutical firm based in the United States currently in its clinical development phase, revealed in February 2023 that the U.S. Food and Drug Administration (FDA) had granted acceptance and priority review status to their new drug application (NDA) concerning nirogacestat, intended for the therapeutic management of adult patients diagnosed with desmoid tumors. The mechanism by which nirogacestat is believed to operate involves impeding the generation of notch proteins, a process that may subsequently trigger the demise of tumorous cells, given that desmoid tumors are known to exhibit elevated levels of notch protein, a factor implicated in their proliferation. Consequently, nirogacestat offers individuals affected by this condition a novel therapeutic avenue with the potential for enhanced treatment results.
Desmoid Tumors Market Major Participants And Competitive Dynamics
Major companies operating in the desmoid tumors market are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Amgen Inc., Eisai Limited, Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Blueprint Medicines Corporation, Debiopharm Group, Clovis Oncology Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG
Access The Complete Desmoid Tumors Market Report:
https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report
Desmoid Tumors Market Global Footprint: Which Region Holds Market Leadership?
North Americawas the largest region in the desmoid tumors market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
